The 0.4% Problem: Why 99% of Your Rybelsus Pill Is Destroyed Before It Ever Reaches Your Bloodstream

The number that should be on every Rybelsus pill bottle

Oral semaglutide bioavailability is roughly 0.4 to 1 percent.

That number is not controversial. It is not a compounded-pharmacy talking point or a skeptical blogger's calculation. It is on page four of the Rybelsus FDA prescribing information. It comes from the pharmacokinetic studies Novo Nordisk submitted for Rybelsus approval in 2019 and again for the Wegovy pill approval in December 2025.

In plain English: when you swallow a 14-milligram Rybelsus tablet, somewhere between 0.056 and 0.14 milligrams of semaglutide actually reaches your bloodstream. The other 99-plus percent is destroyed, excreted, or never absorbed at all.

That is not a design flaw. It is the best possible outcome for putting a peptide that size into a pill. Understanding why is the single most important concept for anyone taking, considering, or selling oral semaglutide — and it explains everything from the fasting protocol to why the Foundayo pill (a completely different molecule) needed to exist.

The fasting protocol, the pill size, the price, the patient frustration, the compounded-oral skepticism — all of it comes from one fact: peptides don't want to live in a pill.

What bioavailability actually means

Bioavailability is a pharmacology term with a precise definition: the fraction of an administered dose that reaches systemic circulation in an unchanged form. It is expressed as a percentage.

An injectable drug has 100% bioavailability by definition — you inject it directly into the tissue, and essentially all of it reaches the bloodstream. An oral drug has to survive a gauntlet of physical and chemical processes before it can be considered "available" to the body:

• The acidic stomach environment (pH 1–2) that denatures many molecules
• Digestive enzymes that chew up proteins specifically
• The intestinal barrier that blocks most large molecules from passing into the blood
• First-pass metabolism in the liver, which can destroy drugs before they enter general circulation

Different drugs handle these obstacles differently. A small-molecule drug like ibuprofen has bioavailability around 80–100% — it just passes through. A drug like morphine taken orally has bioavailability around 40% because of liver first-pass metabolism. Insulin, another peptide, has bioavailability so low that no oral insulin product has ever succeeded commercially.

Semaglutide at 0.4 to 1% sits in the same difficulty bracket as oral insulin. The only reason Rybelsus works at all is a specific formulation trick called SNAC — and that trick is what creates the fasting protocol everyone hates.

Why peptides fail the oral test

Semaglutide is a peptide. Specifically, it is a 31-amino-acid chain with a molecular weight of approximately 4,113 daltons. Tirzepatide (the other major GLP-1) is even larger at 4,813 daltons. Both are in the size range where oral absorption is, frankly, supposed to fail.

The stomach acid problem

Your stomach is designed to unfold proteins. Stomach acid is, from the stomach's perspective, a feature — it denatures proteins in food so that digestive enzymes can break them into absorbable amino acids. That process does not distinguish between the protein in your steak and the peptide in your pill. A naked semaglutide molecule dropped into gastric fluid lasts about as long as a snowflake on a hot sidewalk.

The intestinal barrier problem

Your gut lining is selectively permeable. Small molecules get through easily. Nutrients get their own transporter proteins that shuttle them across. But large molecules — proteins, peptides, most pathogens — cannot cross the intestinal epithelium in meaningful quantities. This is an evolutionary feature that keeps your body from absorbing every microbial protein you eat.

Semaglutide, at 4,113 daltons, is firmly in the "large molecule" bucket. Even if you could protect it from stomach acid, it would just sit in your gut and eventually be excreted.

The enzyme problem

Beyond acid, your gut has digestive enzymes — pepsin, trypsin, chymotrypsin, and others — specifically designed to cleave peptide bonds. These enzymes evolved to break down dietary protein and they are extremely good at it. Any peptide-based oral drug has to either resist these enzymes or be delivered so quickly into circulation that the enzymes do not have time to act.

SNAC: the workaround, not the fix

Novo Nordisk spent roughly a decade figuring out how to make oral semaglutide viable. The solution they landed on is a co-formulation called SNAC — sodium N-[8-(2-hydroxybenzoyl)amino] caprylate, or more mercifully, salcaprozate sodium.

SNAC is an absorption enhancer, which is a polite term for "a chemical that temporarily disrupts the stomach lining in a small, localized area." When a Rybelsus tablet dissolves, the SNAC it contains transiently opens up a small patch of stomach tissue. The semaglutide that happens to be in that patch gets absorbed before the disruption closes.

This is, genuinely, an impressive piece of pharmaceutical engineering. But it has three specific limitations:

Limitation 1: Bioavailability is still only 0.4–1%

Even with SNAC, the absorption window is tiny and most of the semaglutide still misses it. This is why Rybelsus doses look so large (7 mg, 14 mg, up to 25 mg for the Wegovy pill) compared to injectable doses (0.25 mg starting, up to 2.4 mg maintenance). You are dosing for the small fraction that actually gets in.

Limitation 2: The fasting protocol

SNAC works best on a genuinely empty stomach. Food interferes with the absorption window in two ways: it physically gets between the tablet and the stomach lining, and it changes gastric pH and emptying rate. Even normal water intake (more than 4 ounces) dilutes the local SNAC concentration enough to compromise absorption.

This is why Rybelsus and the Wegovy pill must be taken:

• First thing in the morning
• On a completely empty stomach
• With no more than 4 ounces of water
• At least 30 minutes before any food, beverage (including coffee), or other oral medication

These are not lifestyle recommendations. They are pharmacokinetic requirements. Skip or shortcut them and your actual absorbed dose drops below even the 0.4% floor.

Limitation 3: Patient-to-patient variability

Even when taken correctly, absorption varies significantly between individuals and even within the same person on different days. Factors affecting absorption include stomach acidity, gastric emptying rate, and the specific state of the stomach lining that morning. This is why two people on the same Rybelsus dose can have different weight-loss outcomes for reasons that have nothing to do with metabolism.

The math: why Rybelsus doses look absurd

Here is the arithmetic most patients never see:

The top-dose Wegovy pill (25 mg) delivers roughly the same amount of active drug to your bloodstream as a 0.25 mg injection. This is not a weakness of the Wegovy pill — it is just the physics of oral peptide delivery. The pill has to contain ~100 times more drug than the injection to compensate for the absorption losses.

Manufacturing 100 times more drug per dose is not free. This is part of why oral semaglutide products are priced similarly to injectables despite looking like "just a pill" — you are paying for the 99 doses that never reach your blood, not just the 1 that does.

What this means for compounded oral semaglutide

Compounded oral semaglutide — the drops, sublingual tablets, and ODTs sold by telehealth companies — almost universally do not include SNAC or a functionally equivalent absorption enhancer. SNAC is proprietary to Novo Nordisk's formulation.

That means compounded oral semaglutide products face the same absorption challenge as unformulated semaglutide, without the SNAC workaround. Published peer-reviewed human pharmacokinetic data for compounded oral semaglutide (without SNAC) is sparse to nonexistent. We have no robust evidence of meaningful systemic absorption.

This does not mean compounded oral semaglutide "doesn't work." Some patients report weight loss. But the mechanism may involve:

• Placebo effect (real and well-documented in obesity pharmacology)
• The dietary behavior changes that accompany starting any weight-loss program
• A small amount of absorption through the oral mucosa (sublingual route) that has not been well-characterized
• Possibly some gastric absorption when the formulation includes permeability enhancers whose specific mechanisms and quantitative effects have not been published

If Novo Nordisk spent a decade and hundreds of millions of dollars to achieve 0.4% bioavailability with SNAC, it is reasonable to be skeptical when a compounded formulation without SNAC claims comparable effect at a lower price point.

In March 2026, Novo Nordisk's litigation against compounded semaglutide sellers alleged that company testing of some compounded products had identified impurities at levels up to 86 percent — a figure that speaks to broader quality concerns beyond just absorption. The FDA has publicly expressed concerns about unapproved GLP-1 products on multiple quality dimensions: dosing accuracy, storage and stability, active ingredient identity, and impurity profiles.

What actually works orally

Two products have demonstrated meaningful oral bioavailability for the GLP-1 receptor:

1. Rybelsus / Wegovy pill (with SNAC)

The peptide-plus-SNAC approach. Bioavailability 0.4–1%, but with published pharmacokinetic data, FDA-approved dosing, and known clinical outcomes. Requires the fasting protocol. Approved for T2D (Rybelsus) and weight loss (Wegovy pill).

2. Foundayo (orforglipron)

The small-molecule approach that sidesteps the peptide problem entirely. Not a peptide, so no absorption barriers to work around. Taken any time of day, with or without food. Bioavailability in the range of conventional small-molecule drugs. FDA-approved April 1, 2026 for chronic weight management.

Bottom line

Oral peptide GLP-1 is, at its best, a 0.4–1% game. That is the ceiling imposed by biology, and it explains almost every strange feature of Rybelsus and the Wegovy pill: the fasting protocol, the dose size, the price, the patient-to-patient variability. Novo Nordisk's SNAC formulation is impressive engineering that works within these limits — not around them.

For oral GLP-1 that sidesteps the peptide problem entirely, Foundayo's small-molecule approach is the current state of the art. For compounded oral semaglutide, the absorption question is open in a way that many telehealth websites do not acknowledge. Before you decide what to take, know which molecule you are actually getting and how much of it is likely to reach your bloodstream.